In this article BMY Follow your favorite stocks CREATE FREE ACCOUNT Bristol Myers Squibb's Cobenfy drug Courtesy: Bristol Myers Squibb The Food and Drug Administration on Thursday approved Bristol Myers Squibb 's highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades. Schizophrenia affects how a person thinks, feels and behaves, and can cause paranoia, delusions, hallucinations, and changes in emotions, movements and behavior. Those symptoms can disrupt a patient's everyday life, making it difficult to go to school or work, socialize and complete other daily activities.
Most people are diagnosed in their late teens to early 30s . Bristol Myers Squibb expects the twice-daily pill, which will be sold under the brand name Cobenfy , to be available in late October, executives told CNBC. The drug is a badly needed new option for the nearly 3 million adults in the U.
S. living with schizophrenia, some medical experts say. Only 1.
6 million of those patients are treated for the condition, and 75% of them stop taking existing medications in the first 18 months because they struggle to find treatments that are effective or easy for them to tolerate, according to the drugmaker. Cobenfy could also be a huge long-term sales opportunity for Bristol Myers Squibb, which faces pressure to offset the potential loss of revenue from top-selling treatments that will see their patents expire. The drug.